Transaction DateRecipientSharesTypePriceValue
15th October 2020Gregory S Patrick15,000Open or private sale$20.03$300,507.00
15th October 2020Gregory S Patrick15,000Exercise of derivative$12.98$194,700.00
1st October 2020Georges Gemayel14,090Sale back to the issuer$0.00
27th August 2020Gregory S Patrick1,120Bona fide gift$0.00
25th August 2020Gregory S Patrick1,000Bona fide gift$0.00
5th August 2020Georges Gemayel10,000Exercise of derivative$14.84$148,400.00
5th August 2020Georges Gemayel10,000Open or private sale$33.00$330,000.00
29th July 2020Georges Gemayel10,000Open or private sale$30.00$300,000.00
29th July 2020Georges Gemayel10,000Exercise of derivative$14.84$148,400.00
27th July 2020Jack A. Khattar15,625Grant/award etc.$0.00
Supernus Pharmaceuticals
Supernus Pharmaceuticals logo

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The company was founded by Jack A. Khattar on March 30, 2005.

Ticker: SUPN
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1356576
Employees: 464
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $226 M (24%)
Marketable Securities, Current: $175 M (5%)
Inventory, Net: $24 M (0%)
Assets, Current: $557 M (17%)
Property, Plant and Equipment, Net: $18 M (0%)
Other Assets, Noncurrent: $538 Th (-12%)
Assets: $1 B (2%)
Accounts Payable, Current: $3 M (-69%)
Liabilities, Current: $168 M (4%)
Other Liabilities, Noncurrent: $10 M (3%)
Liabilities: $576 M (2%)
Common Stock, Value, Issued: $53 Th (0%)
Common Stock, Shares, Issued: $53 M (0%)
Retained Earnings (Accumulated Deficit): $221 M (10%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $166 Th (-97%)
Stockholders' Equity (Parent): $613 M (0%)
Liabilities and Equity: $1 B (2%)
Cost of Revenue: $4 M (12%)
Research and Development: $19 M (23%)
Operating Income/Loss: $29 M (14%)
Provision for income taxes: $8 M (0%)
EPS (basic): $0.41 (0%)
EPS (diluted): $0.4 (0%)